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Background. Screening for tuberculosis prior to highly active antiretroviral therapy (HAART) initiation is
not routinely performed in low-incidence settings. Identifying factors associated with developing tuberculosis
after HAART initiation could focus screening efforts.
Methods. Sixteen cohorts in the United States and Canada contributed data on persons infected with human
immunodeficiency virus (HIV) who initiated HAART December 1995–August 2009. Parametric survival models
identified factors associated with tuberculosis occurrence.
Results. Of 37 845 persons in the study, 145 were diagnosed with tuberculosis after HAART initiation. Tuberculosis
risk was highest in the first 3 months of HAART (20 cases; 215 cases per 100 000 person-years; 95% confidence interval
[CI]: 131–333 per 100 000 person-years). In a multivariate Weibull proportional hazards model, baseline CD41
lymphocyte count ,200, black race, other nonwhite race, Hispanic ethnicity, and history of injection drug use were
independently associated with tuberculosis risk. In addition, in a piece-wiseWeibull model, increased baselineHIV-1 RNA
was associated with increased tuberculosis risk in the first 3 months; male sex tended to be associated with increased risk.
Conclusions. Screening for active tuberculosis prior to HAART initiation should be targeted to persons with
baseline CD4 ,200 lymphocytes/mm3 or increased HIV-1 RNA, persons of nonwhite race or Hispanic ethnicity,
history of injection drug use, and possibly male sex.
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The risk of developing tuberculosis among persons infected
with human immunodeficiency virus (HIV) has been reported
to be extremely high in the first 3 months after initiation
of highly active antiretroviral therapy (HAART), with rates
ranging from 1300 to 1700 per 100 000 person-years in developed
countries [1, 2] and from 10 700 to 23 000 per 100 000 person-
years in developing countries [2, 3]. Tuberculosis diagnosed after
HAART initiation may represent previously undiagnosed prev-
alent disease, newly acquired tuberculosis (ie, acquired since
HAART initiation), or progression of subclinical tuberculosis
that was not recognized prior to initiation of antiretroviral
therapy (so-called tuberculosis unmasking) [4]. A subset of
persons in the latter group may have immune reconstitution
inflammatory syndrome, with a severe and/or pronounced clin-
ical presentation [5–7]. With continued use of HAART, tu-
berculosis risk decreases over time, although the risk remains
higher than in HIV-seronegative persons [1–3]. Tuberculosis
rates shortly after HAART initiation could potentially be de-
creased if screening for active tuberculosis prior to HAART
initiation were optimized. In the United States, it is recom-
mended that persons infected with HIV undergo screening
for latent Mycobacterium tuberculosis infection at the time of
HIV diagnosis, and annually thereafter if they are at high risk
for exposure to tuberculosis [8]. However, the guidelines do
not address screening prior to HAART initiation—for either
latent M. tuberculosis infection or active disease. Screening
for tuberculosis prior to HAART initiation is not routinely
performed in the United States and Canada [9, 10].
Risk factors for developing tuberculosis shortly after HAART
initiation are incompletely understood. Predisposing factors
in developed countries include low CD41 lymphocyte count
prior to HAART initiation and HIV transmission risk factors
of heterosexual sex and injection drug use [1, 2]. In developing
countries, risk factors include low CD41 lymphocyte count,
younger age, and male sex [2]. However, in a study from South
Africa, only low CD41 lymphocyte count in the 4 months
prior to tuberculosis diagnosis was significantly associated with
increased tuberculosis risk during antiretroviral therapy [3].
Low CD41 lymphocyte count prior to antiretroviral therapy
initiation also appears to be associated with ‘‘tuberculosis
unmasking’’ [5, 7, 11].
Unmasked tuberculosis can become acid-fast bacillus smear-
positive and therefore perhaps more readily transmitted to
others than subclinical disease [7]. In one study, tuberculosis
diagnosed in AIDS patients during the first 3 months of anti-
retroviral therapy was also associated with a 3-fold higher mor-
tality rate than when diagnosed before or more than 3 months
after antiretroviral therapy initiation [12]. The authors suggested
that patients with tuberculosis unmasking have a higher mor-
tality rate due to delays in tuberculosis diagnosis and initiation
of antituberculosis therapy. A better understanding of the risk
factors for developing tuberculosis in the first few months after
antiretroviral therapy initiation—the objective of the present
analysis—can help inform screening strategies to target pa-




Data were collected as part of the North American AIDS
Cohort Collaboration on Research and Design (NA-ACCORD)
of the International epidemiological Databases to Evaluate AIDS
(IeDEA) initiative. The NA-ACCORD was established in 2006
as a regional collaboration of existing single-site and multisite
cohorts from the United States and Canada. Details on the col-
laboration and participating sites have been published elsewhere
[13, 14]. Both interval and clinical cohorts were included, sites
used methods to eliminate duplicate participants in more than
one study cohort, and each cohort used standardized data col-
lection methods. The participating cohorts and this study were
approved by local institutional review boards.
For the current study, we identified persons infected with
HIV from 16 cohorts who initiated HAART after cohort en-
rollment. The study period was from 1 December 1995 through
1 August 2009, although not all cohorts contributed data
throughout the entire study period. Requirements for inclusion
in this analysis were as follows: (1) confirmed HIV infection as
evidenced by documented positive HIV antibody test, detectable
plasma HIV-1 RNA, or a confirmed AIDS-defining event [15];
(2) known sex and year of birth; (3) available historical data
prior to first study visit, including AIDS-defining events, use of
antiretroviral therapy, CD41 lymphocyte counts, and HIV-1
RNA; (4) at least 1 follow-up visit within 12 months of the
initial study visit; and (5) initiation of a HAART regimen prior
to 1 August 2009.
The primary endpoint for this study was tuberculosis di-
agnosed after HAART initiation. Individuals with tuberculosis
diagnosed prior to HAART initiation were excluded. Persons
with AIDS-defining events other than tuberculosis and per-
sons who received non-HAART antiretroviral therapy prior to
HAART initiation were included in the study population.
Study Definitions
HAART was defined as a regimen of at least 30 days duration
that contained at least 3 antiretroviral drugs, one of which had
to be a protease inhibitor (PI; with or without ritonavir boost-
ing), a nonnucleoside reverse transcriptase inhibitor (NNRTI),
one of the nucleoside reverse transcriptase inhibitors (NRTI)
abacavir or tenofovir, an integrase inhibitor (eg, raltegravir),
or an entry inhibitor (eg, maraviroc or enfuvirtide). Persons
who received 3 drugs, of which 2 were zidovudine and stavu-
dine, were excluded. The months that individual antiretroviral
drugs were started and stopped were collected to construct the
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treatment periods. Baseline CD41 lymphocyte counts and HIV-
1 RNA were within 12 months prior to HAART initiation. Black
race in the Canadian cohorts included some persons from in-
digenous populations, and thus was characterized separately
from black race in US cohorts.
All tuberculosis cases were confirmed by local investigators.
For all tuberculosis cases diagnosed ,3 months after HAART
initiation, both the date of antiretroviral therapy initiation and
tuberculosis diagnosis date were reconfirmed by local site in-
vestigators. In general, tuberculosis diagnosis date was defined
as the date of anti-tuberculosis therapy initiation. Pulmonary
tuberculosis was defined as disease affecting the pulmonary
parenchyma. Extrapulmonary disease included disease of the
pleura or any extra-thoracic site. Culture-negative tuberculosis
was established by signs, symptoms, and chest radiography
consistent with tuberculosis, pathology with necrotizing granu-
lomas and acid-fast bacilli, positive nucleic acid amplification
test, and/or clinical response to antituberculosis therapy.
To assess the risk of tuberculosis recurrence, person-time
accumulation began at the end of antituberculosis treatment.
Persons without information on start and stop dates of tuber-
culosis treatment were assumed to receive 6 months of treat-
ment (the standard of care) [16] from the time of tuberculosis
diagnosis.
Statistical Analysis
Groups were defined according to when tuberculosis was di-
agnosed in relation to HAART initiation. Continuous variables
were compared with the Wilcoxon rank-sum test. Categorical
variables were compared with the Fisher exact test. Persons with
missing CD41 lymphocyte and HIV-1 RNA measurements
had values imputed multiple times (20 iterations) using multiple
imputation by chained equations [17, 18], and measurements
underwent Box-Cox transformation to ensure approximately
normal distributions for the multiple imputation [19]. Multiple
imputation was conducted in SAS 9.2 using the IVEware
package for SAS [20]. In addition, race/ethnicity and injection
drug use were also imputed for persons in whom such data were
missing (Supplementary Table 1). All variables (age, sex, race,
injection drug use, HAART regimen type, antiretroviral therapy
naive, CD41 lymphocytes, log10HIV-1 RNA, year of HAART
start, cohort) including time (time from HAART initiation) and
outcome (tuberculosis) were included in the imputation process.
Tuberculosis incidence rates were determined per 100 000
person-years of follow up; 95% confidence intervals (CI) were
calculated using exact Poisson probabilities. To determine
risk factors for tuberculosis after HAART initiation, univari-
ate and multivariate Weibull proportional hazards models
were performed. Graphical plots assessed Weibull assumptions
and demonstrated that theWeibull distribution was appropriate.
To assess whether covariates had different relationships to tu-
berculosis risk ,3 months versus $3 months after HAART
initiation, a piece-wise Weibull model was used, allowing for
a change in the underlying hazard starting at 3 months [21]. We
first compared whether this change-point model fit better than
the standard Weibull model with all covariates included using
Akaike’s Information Criterion (AIC). Interaction terms be-
tween covariates and time interval were added until the AIC
was minimized. Then a process of removing main effect terms
and addition of remaining interaction terms was assessed for
improving model fit until a final model was identified by AIC.
RESULTS
There were 37 845 persons included in the study, of whom 145
(0.4%) were diagnosed with tuberculosis after HAART initia-
tion. The demographic and clinical characteristics of the study
population are in Table 1. The median length of follow up was
4.7 years (IQR: 2.0–8.3 years). There were 22 459 (59%) patients
who were antiretroviral therapy-naive at the time of HAART
Table 1. Demographic and Clinical Characteristics of the Study
Population
Characteristic Number Denominatora % or IQR
Median age, years 39 33–45
Male sex 28 980 77
Race 32 142
White 13 860 43
Black 12 360 38
Hispanic 4735 15
Otherb 1187 4
Injection drug use as
HIV risk factorc
6253 32 973 19
HAART type
PI-based 21 023 56
NNRTI-based 12 302 33





Prior to HAARTc 207 24 642 77–346
Median HIV-1 RNA
(copies/mL)
Prior to HAARTc 48 312 22 989 6432–183 677
Developed confirmed






NOTE. There were 37 845 persons in the study. Data presented pertain to
those persons for whom data were available. HAART, highly active antiretroviral
therapy; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase; PI, HIV-1 protease inhibitor;
TB, tuberculosis.
a Number of persons with available data is 37 845 unless otherwise noted.
b Includes American Indian, Asian, Pacific Islander, and multiracial.
c Within 12 months prior to HAART initiation.
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initiation; the remaining 15 386 (41%) had received non-HAART
antiretroviral therapy prior to HAART initiation. Characteristics
of the 145 persons who developed tuberculosis are in Table 2,
stratified by timing of diagnosis following HAART initiation.
Compared with persons diagnosed $3 months after initiation,
the 20 patients who developed tuberculosis ,3 months after
HAART initiation were older, tended to be male, have lower
median baseline CD41 lymphocyte count, higher median
baseline HIV-1 RNA, and less time in care prior to HAART
initiation. There was no statistically significant difference in the
risk of time to death after tuberculosis diagnosis. The relative
hazard was 1.48 (95% CI: 0.61–3.63; P 5 .39) for persons with
tuberculosis diagnosed in the first 3 months of HAART compared
with $3 months after HAART initiation.
The risk of tuberculosis was highest in the first 3 months after
HAART initiation and highest in the first month (Table 3). The
tuberculosis incidence rate declined after the first month on
HAART, but it became significantly lower than during the first
3 months only after persons had been on antiretroviral therapy
for .6 months.
Table 2. Demographic and Clinical Characteristics of Persons Diagnosed With Tuberculosis, Stratified by Timing of Tuberculosis
Diagnosis in Relation to Antiretroviral Therapy Initiation
Characteristic
,3 months $3 months
P value3
(n 5 20) (n 5 125)
n (%) n (%)
Median age, years (IQR)1 41 (36–45) 37 (31–42) .03
Male sex 18 (90) 86 (69) .06
White 6/17 (35) 23/104 (22) .276
Black (US and Canada) 6/17 (35) 55/104 (53)
Hispanic 3/17 (18) 21/104 (20)
Other 2/17 (12) 5/104 (5)
IDU 6/17 (35) 32/113 (28) .576
HAART type
PI-based 13 (65) 71 (57) .82
NNRTI-based 6 (30) 42 (34)
PI 1 NNRTI or . 3 NRTI 1 (5) 12 (10)
TB culture
Positive 16 (80) 82 (66) .36
Negative 3 (15) 36 (29)
Unknown 1 (5) 7 (5)
Site of TB disease
Pulmonary 9 (45) 81 (65) .26
Extrapulmonary 6 (30) 21 (17)
Both 3 (15) 11 (9)
Unknown 2 (10) 12 (10)
Median CD4 prior to HAART (IQR)2 61 (32–150) 134 (57–234) .04
Mean CD4 (95% CI) including imputed values 82 (41, 142) 135 (104, 171) .05
Median HIV-1 RNA prior to HAART (IQR)3 217 344 (77 473–291 594) 64 069 (14 399–184 291) .05
Mean HIV-1 RNA (95% CI) including imputed values 135 026 (56 252–290 805) 50 536 (29 107–83 871) .06
Died 6 (30) 24 (19) .397
Time in care before HAART initiation (days)5 22 (1–350) 173 (17–829) .06
Median year of HAART initiation 2002 (1999–2004) 1999.5 (1998–2002) .11
NOTE. When data were not available for the entire group, the number of persons with data available is provided. CI, confidence interval; HAART, highly active
antiretroviral therapy; IDU, injection drug use as HIV risk factor; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI; nucleoside
reverse transcriptase inhibitor; PI, HIV-1 protease inhibitor; TB, tuberculosis.
1 At time of HAART initiation.
2 Median and IQR prior to multiple imputation; 7 individuals with TB diagnosed ,3 months and 44 individuals diagnosed $3 months had no CD4 within 12 months
prior to HAART initiation.
3 Median and IQR prior to multiple imputation; 9 individuals with TB diagnosed ,3 months and 54 individuals diagnosed $3 months after HAART start were
missing a HIV-1 RNA measurement within 12 months prior to HAART initiation.
4 Tests were either Fisher’s exact or Wilcoxon rank-sum test as appropriate.
5 Time in care before HAART initiation is defined as time from first CD4 measurement to initiation of HAART among those with a CD4 prior to HAART initiation.
6 Comparison of race and IDU by timing of TB remained insignificant after imputation (P 5 .31 and .44, respectively).
7 P value is from a Cox proportional hazards model, comparing time to death from TB diagnosis among those with ,3 months between HAART initiation and TB
diagnosis versus those with $3 months.
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Tuberculosis risk was not constant over time after HAART
initiation (Table 3), motivating the use of Weibull proportional
hazards models to identify risk factors for tuberculosis over
the duration of follow up after HAART initiation (Table 4). In
univariate analyses, black race, other nonwhite race, Hispanic
ethnicity, history of injection drug use, being antiretroviral
therapy-naive, baseline CD41 lymphocyte count,200 cells/mm3,
and increased baseline HIV-1 RNA were all associated with
a significantly increased risk of tuberculosis. In a multivariate
model, black and other nonwhite race, Hispanic ethnicity,
history of injection drug use, and baseline CD41 lymphocyte
count ,200 cells/mm3 remained significantly associated with
tuberculosis risk after adjusting for cohort and other remaining
variables in the model (Table 4). Tuberculosis risk was not
significantly different among persons with baseline CD41
lymphocyte count 200–350 versus .350 cells/mm3 (relative
hazard 5 1.16; 95% CI: 0.57–2.35; P 5 .68), so these strata
were combined to simplify the model.
To assess for predictors of tuberculosis risk in the first
3 months after HAART initiation, a multivariate piece-wise
Weibull model was performed, evaluating interactions between
tuberculosis predictor variables and time after HAART initiation
(,3 months vs. $3 months). The model with the best fit is
presented in Table 5. Baseline HIV-1 RNA and sex both had
an interaction with time, although the interaction with sex
was of borderline significance (P5 .09). For every 1 log increase
in baseline HIV-1 RNA, the relative hazard of tuberculosis was
1.93 in the first 3 months, but 0.99 $3 months after HAART
initiation. Compared to women, men had a relative hazard of
tuberculosis of 3.13 in the first 3 months, but 0.78 $3 months
after HAART initiation. The other variables in the model had
no interaction with time, and therefore similar relative hazards
throughout the entire follow-up period. Results were similar
when the analysis was limited to persons with complete data
(ie, no multiple imputation), although the 95% confidence
intervals were wider due to the lower number of tuberculosis
cases (Supplementary Table 2).
Of the 145 tuberculosis cases diagnosed after HAART start,
137 contributed follow-up time after tuberculosis diagnosis
(6 individuals died while on tuberculosis treatment or within
6 months of tuberculosis diagnosis, and 2 did not contribute
follow up). There were 93 individuals with both start and
stop dates of anti-tuberculosis therapy available, among
whom the median time to complete treatment was 9.1 months
(IQR: 7.3–12.0). The median duration of follow up after
completion of anti-tuberculosis therapy was 43 months (IQR:
17–65). Of the 137 tuberculosis patients, 2 (1.5%) developed
recurrent disease (incidence rate: 390 per 100 000 person-
years of follow up (95% CI: 50–1410 per 100 000 person-
years). Of the 2 patients with recurrent tuberculosis, one had
a third tuberculosis episode.
Of the 145 tuberculosis cases, 92 (63%) were known to have
received tuberculin skin testing (TST), of whom 59 (64%) of
92 had a positive TST, and 23 (39%) of 59 received treatment
of latentM. tuberculosis infection prior to tuberculosis diagnosis.
DISCUSSION
Several aspects of this observational study should be noted.
First, it was large and included data from more than 37 000
HIV-infected persons who initiated antiretroviral therapy
in 16 cohorts from across the United States and Canada. This
enhances the generalizability of the results to this region. Second,
tuberculosis risk was highest in the first 3 months of HAART.
This finding is consistent with previous studies conducted in
both the developed and developing world [1–3]. However, the
tuberculosis incidence rate during the first 3 months (215 per
100 000 person-years) was substantially lower than has





per 100 000 (PY) 95% CI2
Cumulative
incidence rate
per 100 000 PY 95% CI2
HAART initiation ,1 month 8 3152 254 109–500 254 109–500
.1 month–, 3 months 12 6137 196 101–342 215 131–333
.3 months–# 6 months 13 8906 146 78–250 181 125–255
.6 months–# 1 year 16 16 801 95 54–155 140 103–185
.1 year–# 2 years 21 30 298 69 43–106 107 84–136
.2 years–# 3 years 23 26 450 87 55–131 101 82–124
.3 years–# 4 years 17 22 923 74 43–119 96 79–116
.4 years–# 5 years 7 19 580 36 14–74 87 72–104
.5 years–#12 years 28 64 675 43 29–62 73 61–86
NOTE. CI, confidence interval; HAART, highly active antiretroviral therapy. P values for the comparison of the incidence rate for the indicated time interval
versus the first 3 months after HAART initiation using a Poisson model: 3–6 months, .28; 6 months–1 year, .02; 1–2 years, ,.001; 2–3 years, .003; 3–4 years,
.001; 4–5 years, ,.001; 5–12 years, ,.001.
1 For persons with less than 1 month, 1 month accumulated.
2 95% CI determined via exact Poisson probabilities.
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previously been reported, even in developed world settings
(1300–1700 per 100 000 person-years) [1, 2]. Although the
reason is unclear, it may be due to differences in patient
population, tuberculosis prevalence, or implementation of tu-
berculosis prevention strategies. In addition, we included
persons who had previously received non-HAART antiretroviral
therapy; tuberculosis risk could be higher among persons naive to
antiretroviral therapy. Third, tuberculosis diagnosed in the first
3 months of antiretroviral therapy was not associated with
a significantly higher mortality risk than tuberculosis diagnosed
subsequently. This finding (from a low-incidence region)
differs from findings reported from Haiti [12] but is consistent
with a study from Uganda (both high-incidence countries) [22].
Tuberculosis diagnosed within the first 3 months of HAART
may be due to incomplete immune reconstitution—insufficient
to prevent disease—or unmasking of previously undiagnosed
tuberculosis. The latter may be particularly important in a set-
ting with low rates of M. tuberculosis transmission, such as
the United States and Canada. Such disease was either
not clinically apparent prior to the initiation of antiretroviral
therapy, or the signs and symptoms were attributed to
processes other than tuberculosis. This possibility highlights
the importance of determining the risk factors associated with
such tuberculosis cases, so that these patient groups can be
targeted for tuberculosis screening just prior to antiretroviral
therapy initiation or within the initial months of treatment
initiation.
In this study, the risk factors independently associated
with tuberculosis diagnosis after HAART initiation were black
race, other nonwhite race, Hispanic ethnicity, a history of
injection drug use, and baseline CD41 lymphocyte count
,200 cells/mm3. Persons who were antiretroviral therapy-
naive tended to have an increased tuberculosis risk, but it was
not statistically significant in the multivariate models (Table 4).
The piece-wise Weibull model identified an increased tuber-
culosis risk with HIV-1 RNA levels within the first 3 months
of HAART that was 2-fold increased risk for every 1 log
increase in HIV-1 RNA (Table 5). The increased tuberculosis
risk among men in the first 3 months of HAART was of
borderline statistical significance. The findings were similar
when the analysis was limited to persons with complete data
(ie, no imputation; Supplementary Table 2), although perhaps
Table 4. Weibull Proportional Hazards Model Examining Time to Tuberculosis Diagnosis After HAART Initiation




(95% CI) P value
Relative hazard
(95% CI) P value
Age (per year) 145 (199 779) 0.88 (.73–1.05) .16 0.89 (.73–1.08) .23
Male sex 104 (152 392) 0.79 (.55–1.13) .20 0.96 (.64–1.43) .83
Race
Black—Canada 13.6 (5232.5) 5.92 (3.05–11.48) ,.001 14.02 (2.73–72.0) .002
Black—USA 55.0 (60 130.0) 2.07 (1.38–3.09) ,.001 1.57 (.99–2.48) .053
Hispanic 26.1 (28 606) 2.09 (1.25–3.50) .005 2.29 (1.35–3.89) .002
Other 7.8 (6587.6) 2.74 (1.21–6.19) .015 2.68 (1.17–6.15) .020
White 42.4 (99 223) 1.0 . 1.0 .
IDU 46.4 (43 910) 1.63 (1.15–2.33) .007 1.71 (1.15–2.55) .008
HAART type
PI based 84 (121 542) 1.0 1.0 .
NNRTI 48 (54 813) 1.16 (.82–1.66) .40 1.19 (.82–1.73) .37
Other2 13 (23 424) 0.76 (.43–1.37) .37 0.78 (.43–1.41) .40
Antiretroviral therapy naive (yes vs no) 92 (104 531) 1.46 (1.03–2.05) .03 1.23 (.85–1.80) .28
CD4
0,CD4#50 37.1 (34 645) 2.48 (1.47–4.20) ,.001 2.10 (1.21–3.64) .009
50,CD4#100 27.2 (22 437) 2.83 (1.60–5.02) ,.001 2.47 (1.36–4.49) .003
100,CD4#200 37.6 (41 866) 2.10 (1.29–3.40) .003 1.90 (1.16–3.12) .011
CD4 . 200 43.1 (100 831) 1.0 . 1.0 .
log10(HIV RNA)
1 145 (199 779) 1.26 (1.03–1.53) .02 1.05 (.85–1.31) .64
Year of HAART Initiation (per year) 145 (199 779) 1.04 (.98–1.10) .19 1.01 (.95–1.08) .74
NOTE. CI, confidence interval; HAART, highly active anitretroviral therapy; IDU, injection drug use as HIV risk factor; NNRTI, non-nucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, HIV-1 protease inhibitor.
1 Value prior to HAART initiation. Multiple imputation was used for missing values for CD4 and HIV RNA.
2 Other corresponds to those who had PI and NNRTI, 31 NRTI, or an entry/fusion inhibitor based regimen.
3 Mean number of events and person-years are presented for categories that are affected by multiple imputation resulting in non-integer values for the number of
TB events.
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slightly weaker for HIV-1 RNA and slightly stronger for male
sex.
The finding that lower CD41 lymphocyte count was asso-
ciated with early tuberculosis risk was consistent with several
prior reports [1–3]. Of note in the present study, tuberculosis
risk was similarly increased in the 3 categories of baseline
CD41 lymphocytes #200 compared with CD41 lymphocyte
count .200 cells/mm3.
A history of injection drug was also associated with accel-
erated tuberculosis risk in this study. This finding is consistent
with previous studies of tuberculosis risk after antiretroviral
therapy initiation [1], as well as reports from the United States
demonstrating an association between substance abuse (including
injection drug use) and tuberculosis [23].
Black race, other nonwhite race, and Hispanic ethnicity have
not previously been associated with increased tuberculosis risk
after HAART initiation to our knowledge. However, this
finding is not unexpected in the United States and Canada,
where such groups have a disproportionately high tuberculosis
risk in the general population, irrespective of HIV status [24].
It is unclear why persons of black race in Canada appeared
to have a higher tuberculosis risk than blacks in the United
States, but this may be due in part to differences in how black
race was characterized in these 2 countries.
Although tuberculosis risk was lower than previously re-
ported and decreased with time on HAART, it was still sig-
nificantly higher than in the general population of the United
States and Canada even after .5 years of HAART. The tuber-
culosis incidence rate in such persons in our study was 43 per
100 000 person years—more than 8-fold higher than the overall
tuberculosis incidence rate in the United States and Canada
during the study period—approximately 5 per 100 000 pop-
ulation [25, 26]. This finding highlights the importance of
continued surveillance for tuberculosis, even after prolonged
HAART use.
The rate of recurrent tuberculosis in this study population
(1.5%; 390 per 100 000 person-years) was low compared with
other studies in North America, even with a long median follow
up of 43 months after completion of antituberculosis therapy.
Recurrent tuberculosis risk among HIV-infected persons in the
United States has been reported as high as 8.3% and 9300 per
100 000 person-years [27, 28]. This suggests a beneficial effect
of HAART on recurrence risk, which would be expected given
the decreased risk of recurrent tuberculosis with increasing
CD41 lymphocyte count [27]. Of note, however, although the
confidence intervals were wide, the tuberculosis recurrence rate
in this study was higher than in the ‘‘high-risk’’ first 3 months
after HAART initiation (215 per 100 000 person-years). This
finding is consistent with studies from high tuberculosis inci-
dence settings without widespread HAART use, in which re-
currence rates exceed incidence rates [29–32]. These findings
provide additional impetus for prevention of tuberculosis in
persons infected with HIV.
Of the tuberculosis cases that had received TST and had a
positive test, only 39% received treatment of latentM. tuberculosis
infection prior to tuberculosis diagnosis. This observation is
consistent with other studies that have identified potentially
preventable tuberculosis cases among HIV-infected persons [9].
A strategy of screening for and treating latent infection is
effective in preventing tuberculosis among persons infected
with and adds benefit compared with HAART alone [33, 34].
This study had some limitations. First, it was observational,
and tuberculosis was diagnosed not through active screening
of all study participants but as part of ongoing health care for
individuals. Therefore, some tuberculosis cases could have been
missed. However, because patients were in HIV care and tuber-
culosis is a reportable disease, all cases should have been captured
by the individual cohorts. Second, the NA-ACCORD database
included only persons with at least 1 follow-up visit within
12 months of entering observation in the current analysis.
Tuberculosis cases in any persons without such a follow-up
visit would therefore have not been included.
Table 5. Piecewise Weibull Model of Tuberculosis Risk After
HAART Initiation
Multivariate model adjusted for cohort
Relative hazard
(95% CI) P value
Male sex2
,3 months 3.13 (.65–14.19) .16
$3 months 0.78 (.51–1.17) .23
Race
Black—Canada 13.51 (2.78–65.67) .002
Black—USA 1.50 (.97–2.34) .07
Hispanic 2.18 (1.30–3.66) .003
Other 2.84 (1.30–6.18) .009
White 1.0 .
IDU 1.60 (1.11–2.31) .01
Antiretroviral therapy
naive (yes vs no)
1.33 (.94–1.88) .10
CD4
0,CD4#50 1.94 (1.14–3.29) .02
50,CD4#100 2.37 (1.34–4.18) .003
100,CD4#200 1.91 (1.18–3.08) .008
CD4 .200 1.0 .
log10(HIV RNA)
1,2
,3 months 1.93 (1.39–2.69) ,.001
$3 months 0.99 (.80–1.23) .92
NOTE. Tuberculosis risk is dichotomized according to ,3 months versus
$ 3 months after HAART initiation. Shape parameter: ,3 months shape 5
1.33, $3 months space 5 0.92. This analysis includes imputed values for
missing data. CI, confidence interval; HAART, highly active antiretroviral
therapy; IDU, injection drug use as HIV risk factor.
1 Value prior to HAART initiation. Multiple imputation was used for missing
values for CD4 and HIV RNA.
2 Interaction with time after HAART initiation: male sex P value 5 .09; log10
HIV-1 RNA P value , .001.
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In summary, our study highlights the possible benefit of
screening for tuberculosis prior to and shortly after antiretroviral
therapy initiation, even in low tuberculosis incidence areas such
as the United States and Canada. Screening should be focused
on persons with baseline CD41 ,200 lymphocytes/mm3 or
increased HIV-1 RNA, persons of nonwhite race or Hispanic
ethnicity, history of injection drug use, and possibly male sex.
The tuberculosis recurrence rate of 1.5% among persons re-
ceiving HAART illustrates an important paradox: HAART ap-
peared to confer a benefit regarding recurrence risk, but the risk
of recurrent tuberculosis was high relative to tuberculosis risk
among all HIV-infected persons in this study.
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